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Abstract 
There has been discussion and debate in the medical literature regarding the clinical 
value of PET/CT scans in ovarian cancer, particularly focusing on evidence whether the 
technology is of predictive versus solely prognostic utility. In the somewhat unusual case 
reported here, the results of the PET/CT scan were extremely helpful in developing a 
rational management strategy. The case emphasizes the critical need to specifically 
address the issue of whether data generated from an expensive diagnostic test will be 
useful in an individual patient’s management before it is obtained. 
 
Introduction 
There has been considerable discussion in the gynecologic cancer literature regarding 
the potential benefits associated with the performance of a PET/CT scan in women with 
epithelial ovarian cancer, particularly in the setting of suspected or documented recurrent 
disease [1–7]. One recent report noted that 60% of patients with recurrent ovarian cancer 
had their treatment plan modified based on the results of this imaging procedure [1]. 
However, it remains unknown how such changes in management influence the 
patient’s outcome (overall, symptom-free or progression-free survival, quality of life) [8, 
9]. Specifically, one must inquire if the data obtained through the conduct of this 
expensive diagnostic test is of predictive utility (helps select a specific management plan 
predicted to be beneficial due the study findings) or only of prognostic value (defines a  
Case Rep Oncol 2009;2:121–124 
DOI: 10.1159/000228988 
Published online: July 29, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
122
situation where the patient is more/less likely to have a relatively poor/good outcome, 
independent of any particular management strategy) [8, 9]. 
The clinical course of a woman with a long history of epithelial ovarian cancer 
provides a relevant example of the potential for PET/CT scanning to modify management 
in an individual patient and where it is rational to argue that the specific diagnostic data 
in rather unique settings can be considered crucial in defining optimal care. 
Case Report 
A 70-year-old woman presented in January of 2002 with a complex pelvic mass and a CA-125 in the 
350 U/ml range. Her history was complicated by a history of breast cancer. She is of Ashkenazi heritage 
and therefore underwent genetic counseling and BRCA testing. These were negative. 
The patient underwent an exploratory laparotomy and staging with complete resection of all gross 
disease. Final pathology revealed a moderately differentiated papillary serous carcinoma of the ovary. 
She was treated with 6 cycles of carboplatin and paclitaxel, achieving a complete response as measured 
by her CA-125 antigen level. Her post-treatment course was complicated by moderate neuropathy that 
improved but did not completely resolve. 
Two years after the treatment the patient experienced a chronic bowel obstruction secondary to 
adhesions that caused such distressing symptoms that she underwent laparoscopic adhesiolysis. The 
procedure resulted in resolution of her symptoms. There was no evidence of disease with biopsies and 
washings being negative. 
Immediately postoperatively she had a low normal CA-125 level (<13 U/ml range). Over the next 2 
years the CA-125 rose from this level to 18 U/ml, and then ultimately to 28 U/ml. The marker remained 
stable over the next 2 years ranging from 28 to 40 U/ml. CT scans were negative. In 2008, the CA-125 
began to rise slowly and CT scans demonstrated only a small amount of lymphadenopathy with a 2-cm 
node in the left common ileac area not easily accessible for CT-guided biopsy. Attempted biopsy was 
negative. Her CA-125 began to rise more rapidly and in December of 2008 increased to 80 U/ml. The 
CT scan of the abdomen/pelvis remained unremarkable. 
In March of 2009, the marker increased to 118 U/ml. CT remained negative and a PET/CT scan was 
obtained. This test demonstrated military disease throughout the pelvis with many nodules <1 cm, with 
no disease >1 cm in diameter. She did have one retroperitoneal node that was approximately 1.5 cm. 
After an extensive discussion with the patient regarding neuropathy and other comorbidities, she 
and her physician elected to initiate retreatment with carboplatin and gemcitabine. After 3 cycles her 
CA-125 level normalized. The plan is to continue to complete 6 cycles of this regimen, with a follow-up 
PET/CT scan. If the PET/CT is negative or mildly positive for residual disease, antiestrogen therapy will 
be considered. 
Discussion 
Considerable uncertainty surrounds the question of the utility of many innovative 
diagnostic techniques in the oncology arena. In addition to the issue of the specificity 
(does a ‘positive test’ result indicate the presence of cancer, and only cancer) and 
sensitivity (does a ‘negative test’ result indicate the absence of cancer), it is increasingly 
essential to inquire if the information provided is of predictive value or solely of 
prognostic significance [9]. 
Considering the substantial costs associated with novel diagnostic tests, and in 
particular imaging technology, it is appropriate to question the importance of ‘another 
result’ that indicates that the patient will have a relatively favorable versus a relatively 
unfavorable outcome (prognostic utility), but where the data itself does not clearly define  
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a known beneficial management strategy that would only have been employed because of 
the specific test result (predictive utility). 
For example, in recurrent ovarian cancer, a PET/CT finding of ‘diffuse disease 
throughout the peritoneal cavity’, versus the observation of ‘relatively localized cancer’, 
while potentially of prognostic value, will not necessarily permit the selection of therapy 
that impacts survival [8]. Further, the argument that the finding of apparently localized 
disease should lead to surgery, while the observation of diffuse disease should not, is 
currently not supported by any evidence-based (randomized phase 3) clinical trials. Thus, 
we do not know if surgery (to remove the observed masses) in this setting is superior to 
initial treatment with cytotoxic chemotherapy, and conversely it is unknown if patients 
with ‘diffuse disease’ (as documented on PET/CT) are unable to benefit from surgery 
designed to completely remove all macroscopic cancer (of course, leaving the ‘diffuse 
microscopic residual’). 
In the case presented here, there was reasonable uncertainty regarding optimal disease 
management based on the prior medical history (known breast and ovarian cancer, long 
treatment-free interval, persisting neuropathy), as well as nonspecific physical signs and 
symptoms and routine diagnostic tests (abdominal/pelvic CT scan, CA-125). In was 
appropriate to argue in this specific individual with a long treatment-free interval and a 
mass (enlarged lymph node) that could potentially be easily removed that surgical 
resection might permit the patient to go for an additional extended period of time 
without the reintroduction of chemotherapy. Conversely, it was equally possible that the 
lymph node was not the source of the increasing CA-125 levels, and may even have been 
nonmalignant. 
The PET/CT scan findings revealed a very diffuse process in the absence of any large 
masses that would be amenable to surgical resection. The test results provided relevant 
information that reinforced the physician’s decision to employ systemic treatment in this 
individual. Of note, in this patient, with a set of particularly unique clinical features, the 
PET/CT could be utilized in the selection of a specific clinical plan that also included 
consideration of those unique characteristics. 
In the absence of evidence-based data demonstrating the utility of this procedure in the 
management of patients with ovarian cancer, it is essential that clinicians prospectively 
consider (prior to obtaining the test): (a) how the information generated from the 
performance of this expensive imaging modality will influence the selection of specific 
treatment; (b) whether such information will be of genuine utility in a particular patient; 
(c) and whether there are alternative, more cost-effective approaches (physical exam; 
CT-scan; CA-125 value alone; knowledge of the natural history of the malignancy) that 
may be employed to define appropriate care. 
 
 
 
  
Case Rep Oncol 2009;2:121–124 
DOI: 10.1159/000228988 
Published online: July 29, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
124
References 
1  Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M: The impact of 
PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study 
as part of the Australian PET Data Collection Project. Gynecol Oncol 
2009;112:462–468. 
2  Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW: Positive emission 
tomography for evaluating a complete clinical response in patients with ovarian 
or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol 
Oncol 2001;82:17–21. 
3  Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, Buell U: 
2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the 
diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310–315. 
4  Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER: FDG-PET for 
management of cervical and ovarian cancer. Gynecol Oncol 2005;97:183–191. 
5  Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, 
Wahl RL, Montz FJ: Clinically occult recurrent ovarian cancer: patient selection 
for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 
2003;90:519–528. 
6  Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, 
Graeff H, Schwaiger M, Kuhn W: Prediction of response to neoadjuvant 
chemotherapy by sequential F-18-fluorodeoxyglucose positron emission 
tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 
2005;23:7445–7453. 
7  Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ: The impact 
of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 
2006;103:271–276. 
8  Markman M: Use of positron emission tomography scans in ovarian cancer: a 
diagnostic technique in search of an indication. J Clin Oncol 2005;23:7385–7387. 
 